Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Anti-G17 immunogen: Phase II

In a 30-patient U.K. Phase II dose-ranging trial, Anti-G17 gave an overall median survival of

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE